Literature DB >> 23953899

Disadvantages of VKA and requirements for novel anticoagulants.

Raji Shameem1, Jack Ansell.   

Abstract

Vitamin K antagonists have been in wide use for over 70 years. Warfarin, the most commonly used vitamin K antagonist, has been shown to be highly effective in treating and preventing thrombosis. Despite this, warfarin has many disadvantages, which has led to the development of a new class of oral anticoagulants targeted to specific coagulation factors designated as target-specific oral anticoagulants (TSOAs). TSOAs include the thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban). This chapter reviews the disadvantages of warfarin and evaluates both the advantages and disadvantages of the new oral anticoagulants.
© 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  apixaban; dabigatran; oral anticoagulation; rivaroxaban; vitamin K antagonists; warfarin

Mesh:

Substances:

Year:  2013        PMID: 23953899     DOI: 10.1016/j.beha.2013.07.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  18 in total

1.  Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis.

Authors:  Joris Komen; Tomas Forslund; Paul Hjemdahl; Morten Andersen; Björn Wettermark
Journal:  Br J Clin Pharmacol       Date:  2016-11-30       Impact factor: 4.335

Review 2.  Direct oral anticoagulant considerations in solid organ transplantation: A review.

Authors:  David M Salerno; Demetra Tsapepas; Apostolos Papachristos; Jae-Hyung Chang; Spencer Martin; Mark A Hardy; Jaclyn McKeen
Journal:  Clin Transplant       Date:  2016-12-28       Impact factor: 2.863

3.  Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.

Authors:  Marta Cortes-Canteli; Anna Kruyer; Irene Fernandez-Nueda; Ana Marcos-Diaz; Carlos Ceron; Allison T Richards; Odella C Jno-Charles; Ignacio Rodriguez; Sergio Callejas; Erin H Norris; Javier Sanchez-Gonzalez; Jesus Ruiz-Cabello; Borja Ibanez; Sidney Strickland; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2019-10-15       Impact factor: 24.094

4.  Trends in the prescription of novel oral anticoagulants in UK primary care.

Authors:  Simone Y Loo; Sophie Dell'Aniello; Laetitia Huiart; Christel Renoux
Journal:  Br J Clin Pharmacol       Date:  2017-05-04       Impact factor: 4.335

5.  Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR.

Authors:  Sadık Volkan Emren; Oktay Şenöz; Murat Bilgin; Osman Beton; Abdullah Aslan; Uğur Taşkin; Gönül Açiksari; Lale Dinç Asarcikli; Hakan Çakir; Lütfü Bekar; İsmail Bolat; Çağrı Yayla; Barış Çelebi; Onur Dalgiç; Oğuzhan Çelik; Özgen Şafak; Serdar Akyel; Hasan Güngör; Barış Düzel; Mehdi Zoghi
Journal:  Clin Appl Thromb Hemost       Date:  2017-02-19       Impact factor: 2.389

6.  Hospitalizations and deaths related to adverse drug events worldwide: Systematic review of studies with national coverage.

Authors:  Lunara Teles Silva; Ana Carolina Figueiredo Modesto; Rita Goreti Amaral; Flavio Marques Lopes
Journal:  Eur J Clin Pharmacol       Date:  2021-10-30       Impact factor: 2.953

7.  Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.

Authors:  Sadık Volkan Emren; Mehdi Zoghi; Rida Berilgen; İbrahim Halil Özdemir; Oğuzhan Çelik; Nurullah Çetin; Asım Enhoş; Cemal Köseoğlu; Abdurrahman Akyüz; Volkan Doğan; Fatih Levent; Yüksel Dereli; Tolga Doğan; Özcan Başaran; Ilgın Karaca; Özkan Karaca; Yılmaz Ömür Otlu; Çağlar Özmen; Selvi Coşar; Mutlu Sümerkan; Erdal Gürsul; Sinan İnci; Ersel Onrat; Oktay Ergene
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

Review 8.  Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.

Authors:  Klaus Grossmann
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

9.  Global assays and the management of oral anticoagulation.

Authors:  Herm Jan M Brinkman
Journal:  Thromb J       Date:  2015-02-10

10.  Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands.

Authors:  Susan Hanemaaijer; Fong Sodihardjo; Annemieke Horikx; Michel Wensing; Peter A G M De Smet; Marcel L Bouvy; Martina Teichert
Journal:  Int J Clin Pharm       Date:  2015-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.